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Context: Combined infusion of levothyroxine plus liothyronine, as
opposed to levothyroxine alone, is the only way of restoring the con-
centrations of circulating TSH, T4, and T3 as well as those of both T4
and T3 in all tissues of thyroidectomized rats. Considering the sub-
stantial differences in thyroid hormone secretion, transport, and me-
tabolism between rats and humans, whether or not combined levo-
thyroxine plus liothyronine replacement therapy has advantages over
treatment with levothyroxine alone in hypothyroid patients is still
questioned.
Evidence Acquisition:We conducted a systematic review of all the
published controlled studies comparing treatment with levothyroxine
alone with combinations of levothyroxine plus liothyronine in hypo-
thyroid patients, identified through the Entrez-PubMed search
engine.
Evidence Synthesis: Nine controlled clinical trials were identified
that compared treatment with levothyroxine alone and treatment
with combinations of levothyroxine plus liothyronine and included a
sufficient number of adult hypothyroid patients to yield meaningful
results. In only one study did the combined therapy appear to have
beneficial effects on the mood, quality of life, and psychometric per-
formance of the patients over levothyroxine alone. These results have
not been confirmed by later studies using either T3 substitution pro-
tocols or approaches with fixed combinations of levothyroxine plus
liothyronine, including those based on the physiological proportion in
which T3 and T4 are secreted by the human thyroid. However, in some
of these studies the patients preferred levothyroxine plus liothyronine
combinations, for reasons not explained by changes in the psycho-
logical and psychometric tests employed. Yet patients’ preference
should be balanced against the possibility of adverse events resulting
from the addition of liothyronine to levothyroxine, even in the small
doses used in these studies.
Conclusions: Until clear advantages of levothyroxine plus liothyro-
nine are demonstrated, the administration of levothyroxine alone
should remain the treatment of choice for replacement therapy of
hypothyroidism. (J Clin Endocrinol Metab 90: 4946–4954, 2005)
AT PRESENT, SODIUM levothyroxine is the preparationof choice to restore well-being and euthyroidism in
hypothyroid patients (1–3). The latter is believed to occur
when serum TSH returns to the reference range (2), with
serum TSH concentrations usually used to monitor levothy-
roxine therapy. Reliance on circulating TSH is supported by
many years of experience, and most patients are satisfied
with the results, but it implies assumptions that are not
supported by direct evidence.
First, although approximately 80% of the T3 circulating in
blood is originated by peripheral 5-deiodination of the T4
secreted by the thyroid gland, as much as 20% is secreted
directly by the gland (4), suggesting a physiological role for
the latter fraction. When patients are given levothyroxine
alone, it is assumed that peripheral conversion of T4 to T3
provides the exact amount of T3 needed by each particular
tissue or organ that is usually provided by the missing thy-
roid secretion.
But the scarce evidence available for man does not support
this. Hypothyroid patients on levothyroxine replacement
therapy have higher serum T4 levels when serum TSH and
T3 concentrations are similar to those of euthyroid controls
(5). In as many as 25–32% of hypothyroid patients on levo-
thyroxine therapy, serum T4 has to reach the upper limit of
the normal range, or even exceed it, to normalize serum TSH
and its normal response to TSH-releasing hormone (6, 7).
These findings suggest that the levothyroxine doses needed
to normalize serum TSH in hypothyroid patients are rela-
tively supraphysiological, possibly to compensate for the
absence of the fraction of circulating T3 secreted directly by
the thyroid.
Second, TSH is widely used to monitor levothyroxine re-
placement therapy (1–3, 6), assuming implicitly that its level
within the normal range indicates euthyroidism in all tissues
of hypothyroid patients. Serum TSH levels, however, only
reflect the feedback effect of thyroid hormones at the hypo-
thalamic-pituitary level. In patients on long-term replace-
ment with levothyroxine presenting with biochemical ab-
normalities suggestive of hyperthyroidism, free T4 was
raised in 85% of them, whereas an undetectable serum TSH
was present in only 67% (8). Moreover, athyreotic patients
present a differential end-organ responsiveness to subopti-
mal thyroid hormone concentrations (9). It is thus unlikely
that a single end-point of thyroid hormone action, such as
serum TSH, accurately reflects the thyroid hormone concen-
trations in all tissues and organs.
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Combined Levothyroxine plus Liothyronine
Treatment for Hypothyroidism in Animal Models
We have conducted a series of animal studies to evaluate
whether replacement therapy with levothyroxine alone ac-
tually resulted in euthyroidism (10–13). Thyroidectomized
rats received continuous sc infusions of levothyroxine, syn-
thetic T3 (liothyronine), or combinations of levothyroxine
plus liothyronine. Samples of plasma and most tissues were
assayed for thyroid hormone measurements, and types 1, 2,
and 3 deiodinase activities were measured in several tissues
(Fig. 1). Tissue euthyroidism was declared when the con-
centrations of both T4 and T3 were within the normal range
found in intact euthyroid animals infused with placebo.
We found in Refs. 10–13 that: 1) despite a wide range of
doses infused (from 0.2–8.0 g levothyroxine/100 g body
weight per day and from 0.25–2.0 g liothyronine/100 g
body weight per day), neither levothyroxine nor liothyronine
alone restored euthyroidism (Tables 1 and 2); 2) combina-
tions of levothyroxine plus liothyronine, however, based on
the amounts and proportions of T4 and T3 present in the rat
thyroidal secretion, did ensure euthyroidism (Table 3); 3)
with the levothyroxine dose that normalized plasma TSH,
most tissues still had T3 concentrations below the normal
range (Table 1); 4) when levothyroxine plus liothyronine
combinations were infused, the levothyroxine needed to nor-
malize serum TSH was almost half the dose required with
levothyroxine alone (Tables 1 and 3); 5) the mechanisms
involved in the regulation of thyroid hormone concentra-
tions were tissue specific, and so was the efficiency of the
homeostasis of tissue T3 concentrations (Tables 1–3); 6) when
levothyroxine alone was used for replacement therapy, the
cerebral cortex was extremely efficient in maintaining nor-
mal T3 concentrations and was virtually independent from
changes in serum concentrations of T4 and T3 (Table 1); and
7) this excellent homeostasis of brain T3 levels was lost when
liothyronine alone was infused (Table 2).
These conclusions cast doubts upon replacement therapy
in humans with levothyroxine alone (11), because it might
not be able to restore euthyroidism in all tissues of hypo-
thyroid patients. Normalization of serum TSH, the usual
marker of euthyroidism during treatment, might not ensure
normal T3 concentrations in some tissues.
We therefore hypothesized that a combined treatment of
levothyroxine plus liothyronine might be advantageous for
hypothyroid patients, compared with levothyroxine alone
(11). Based on our results in the rat, we made several rec-
ommendations regarding the ideal thyroid hormone prep-
aration (11): 1) it should contain levothyroxine and liothy-
ronine in a molar proportion of 14:1 and deliver into the
circulation approximately 100g T4 and 6g T3 per day, thus
mimicking human thyroid secretion (4), and 2) the route of
administration should warrant a constant steady supply of
levothyroxine and liothyronine, by means of enteric, im, or
transdermal sustained-release preparations, at least for the
T3 component. However, most of the studies conducted in
hypothyroid patients after the publication of our data have
ignored these recommendations, despite being rapidly
adopted by other experts in the field (14).
There are substantial differences between rats and humans
in thyroid hormone secretion, transport, and metabolism.
The molar T4:T3 ratio in thyroid secretion has been calculated
as 14:1 in adult man (4), whereas the corresponding mean
value obtained for the adult male rat is approximately 6:1
(15–18). In humans, thyroid-binding globulin (TBG) is the
principal serum transport protein for thyroid hormones,
whereas only a small proportion circulates bound to transt-
hyretin and albumin. Binding to TBG may serve as a circu-
lating buffer that might partially alleviate the thyroid when
exposed to sudden increases in the requirements of these
hormones. In rat serum, transthyretin is the dominant thy-
roid hormone-binding protein, the concentration of TBG be-
ing extremely low in adults, approximately 2% of that cir-
culating in humans (19, 20). Thyroid hormones’ metabolism
is less buffered by plasma proteins than it is in man, with a
greater proportion circulating as free T4 and free T3 (21, 22).
This may contribute to explain the need of a higher propor-
tion of T3 with respect to T4 secreted by the rat thyroid.
Moreover, the regulation of tissue thyroid hormone con-
centrations involve deiodinative and nondeiodinative path-
ways of T4 and T3 metabolism and factors regulating the
uptake and exit of iodothyronines into organs and tissues
(23–27), and these mechanisms may be both tissue and spe-
cies specific.
These differences between animals and humans ought to
be considered before extending the rat findings to human
physiology and, especially, to the issue of treatment with
thyroid hormone preparations in hypothyroid patients.
Combined Levothyroxine plus Liothyronine
Treatment for Hypothyroidism in Humans
There are few studies comparing levothyroxine replace-
ment therapy with treatments using combinations of levo-
thyroxine plus liothyronine (Table 4). Taylor and his co-
workers observed that patients treated with levothyroxine
alone had increased plasma protein-bound iodine (PBI) val-
ues compared with healthy euthyroid controls. They re-
ported in 1970 (28) that patients’ PBIs were comparable to
those of euthyroid subjects when given tablets containing 50
g levothyroxine plus 15 g liothyronine (Fig. 2), with main-
tenance of clinical euthyroidism.
Some months later, Smith et al. (29) published the first
FIG. 1. Experimental design of our studies in thyroidectomized rats
infused with levothyroxine alone, liothyronine, or levothyroxine plus
liothyronine.
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study comparing levothyroxine therapy with combined
levothyroxine plus liothyronine treatment. Using a double-
blinded, crossover design, they assigned 87 patients to re-
ceive their usual number of tablets (two or three), containing
either 100 g levothyroxine or 80 g levothyroxine plus 20
g liothyronine, with treatments rotated after 2 months.
Adverse effects (palpitations, irritability, nervousness,
dizziness, and tremor) were more frequent during combined
levothyroxine plus liothyronine treatment. Thirty-three per-
cent preferred levothyroxine tablets, 18.4% preferred levo-
thyroxine plus liothyronine tablets, whereas 48.3% showed
no preference. Adverse effects influenced patients’ prefer-
ence (29).
With levothyroxine plus liothyronine, the plasma PBI and
the free T4 index decreased, whereas the T3-resin uptake
values were not altered (29). They concluded that “the short-
comings of combined therapy suggested overall advantages
of thyroxine for replacement therapy” (29). We know now-
adays that all their patients were overtreated, with the ad-
verse effects using the combinations being easily explained
by the addition of 40–60 g liothyronine to an already ex-
cessive levothyroxine dose.
The interest for a combined levothyroxine plus liothyro-
nine therapy declined until the late 1990s, when our animal
studies were published (10–13). Although actually ignoring
our recommendations for man (11), Bunevicius et al. (30)
published in 1999 their favorable experience with combined
levothyroxine plus liothyronine replacement therapy in 33
hypothyroid patients, 31 women and two men, of whom 17
were thyroidectomized thyroid cancer patients and 16 had
chronic autoimmune thyroiditis.
The study was a randomized, double-blinded crossover
trial (30), using what has been named a T3 substitution ap-
proach (31), substitution of a fixed amount of liothyronine for
TABLE 2. Schematic representation of plasma concentrations of T4, T3, and TSH and tissue levels of T4 and T3 in thyroidectomized rats
infused with different doses of liothyronine with respect to age- and sex-matched controls
Dose of T3 (g/100 gd)
0.25 0.50 0.75 1.0 2.0
T4 T3 TSH T4 T3 TSH T4 T3 TSH T4 T3 TSH T4 T3 TSH
Plasma 2  1 2 1 2 2 1 2 2 1 2 2 1 2
Cerebral cortex 2 2 2  2  2  2 1
Cerebellum 2  2  2 1 2 1 2 1
Pituitary 2 2 2  2  2 1 2 1
BAT 2 2 2 2 2  2  2 
Liver 2 2 2 1 2 1 2 1 2 1
Kidney 2 2 2  2 1 2 1 2 1
Lung 2  2 1 2 1 2 1 2 1
Heart 2 2 2 1 2 1 2 1 2 1
Muscle 2  2 1 2 1 2 1 2 1
Spleen 2  2 1 2 1 2 1 2 1
Adrenal 2  2 1 2 1 2 1 2 1
Ovary 2  2  2 1 2 1 2 1
The symbols represent the comparison of the mean values of the liothyronine-infused rats with control rats infused with placebo. , No
statistically significant differences;2, low levels as comparedwith controls, with at leastP 0.05;1, elevated levels as comparedwith controls,
with at leastP 0.05. BAT, Brown adipose tissue. [Representedwith permission from data published inH. F. Escobar-Morreale et al.:Biochimie
(Paris) 81:453, 1999 (13). Elsevier.]
TABLE 1. Schematic representation of plasma concentrations of T4, T3, and TSH and tissue levels of T4 and T3 in thyroidectomized rats
infused with different doses of levothyroxine with respect to age- and sex-matched controls
Dose of T4 (g/100 gd)
0.2 0.4 0.6 0.8 1.0 1.6 2.0 3.0 4.0 8.0
T4 T3 TSH T4 T3 TSH T4 T3 TSH T4 T3 TSH T4 T3 TSH T4 T3 TSH T4 T3 TSH T4 T3 TSH T4 T3 TSH T4 T3 TSH
Plasma 2 2 1 2 2 1  2 1  2 1   1 1   1 1 2 1 1 2 1 1 2 1 1 2
Cerebral
cortex
2 2 2  2  2  1  1 1 1  1  1  1 
Cerebellum 2 2 2 2  2 1    1    1  1 1 1 1
Pituitary 2 2 2 2  2 1 2   1      1 1 1 1
BAT 2     2    
Liver 2 2 2 2 2 2 2 2  2 1  1  1  1 1 1 1
Kidney 2 2 2 2 2 2 2 2  2 1  1 1 1 1 1 1 1 1
Lung 2 2 2 2  2  2  2 1 2 1  1 1 1 1 1 1
Heart 2 2 2 2  2  2  2  2 1  1 1 1 1 1 1
Muscle 2 2  2  2 1  1  1 1 1 1 1  1 1 1 1
Spleen 2 2 2 2  2    2 1 1 1  1 1 1 1 1 1
Adrenal 2 2 2 2  2  2  2 1 2 1   2 1  1 
Ovary 2 2 2 2 2 2  2  2  2        
The symbols represent the comparison of the mean values of the levothyroxine-infused rats with control rats infused with placebo. , No
statistically significant differences;2, low levels as comparedwith controls, with at leastP 0.05;1, elevated levels as comparedwith controls,
with at least P 0.05. BAT, Brown adipose tissue. [Redrawnwith permission from data published in H. F. Escobar-Morreale et al.: J Clin Invest
96:2828, 1995 (10).]
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a fixed amount of the daily levothyroxine dose, irrespective
of total levothyroxine dose received by the patient. For 5-wk
periods, patients received their usual levothyroxine dose, or
a combination in which 50 g levothyroxine was withdrawn
and 12.5 g liothyronine added. Although the order of treat-
ments was randomized, the groups starting on the combi-
nation had normal mean TSH values, whereas those starting
on levothyroxine alone had mean TSH values below the
normal range. The levothyroxine doses ranged from 100–300
g/d, with a mean sd of 175 53 g/d. Therefore, T3 was
not in an enteric sustained-release form, and the molar T4:T3
ratios of the combinations received by the patients were quite
variable, ranging from 3.4:1 (4:1 by wt) to 17:1 (20:1 by wt).
Despite the marked variability in prestudy levothyroxine
doses and serum TSH levels and in the T4:T3 ratios of the
combinations actually administered, Bunevicius et al. (30)
found that the combinations of levothyroxine plus liothyro-
nine improved several indexes of quality of life (QoL), mood,
and psychometric performance (30). Patients preferred levo-
thyroxine plus liothyronine combinations compared with
replacement with levothyroxine alone (30). However, it
should be noted that the statistical analysis applied in this
study did not facilitate any information about possible pe-
riod and sequence effects.
A subsequent reanalysis of the data, removing from the
initial study the data from the two men, from four depressed
women, and from a woman who presented with increased
serum TSH levels at baseline, revealed that the findings
originally reported were maintained only in the subset of
athyreotic patients and not in women with autoimmune
thyroiditis (32). This was unexpected, because the presumed
benefits of T3 substitution were restricted to athyreotic thy-
roid cancer patients, who had received proportionally less
liothyronine than patients with autoimmune thyroiditis. In
the subset of thyroid cancer patients, however, T3 substitu-
tion actually decreased the overall thyroid hormone dose,
and the recovery from an iatrogenic thyrotoxic state might
account for the improvement in QoL, similar to that occur-
ring soon after levothyroxine withdrawal in thyroid cancer
patients (33).
In a later study, Bunevicius et al. (34) tried to reproduce
their initial results in a sample of 10 patients thyroidecto-
mized for Graves’ disease, but no improvements were found
with T3 substitution. However, the very small sample size in
this study precludes a definite conclusion.
The publication of the first study of Bunevicius et al. (30,
32) was greeted with considerable interest not only for sci-
entific reasons but also for hypothyroid patients; combined
levothyroxine plus liothyronine replacement was considered
the answer to the relatively frequent complaint (35) of the
persistence, with levothyroxine alone, of hypothyroid symp-
toms despite normalization of serum TSH.
To date, four published studies (36–39) have tried to re-
produce the beneficial effects of T3 substitution described
above, without success (Table 4). Walsh et al. (36) conducted
a randomized, double-blinded, crossover trial in which pa-
tients were treated with their usual levothyroxine dose or a
combination that contained 50 g less of levothyroxine plus
10 g liothyronine for 10 wk, separated by a 4-wk washout
period on levothyroxine alone. Evaluation of the 101 patients
completing the study revealed no substantial improvement
in indexes of QoL, cognitive function, mood, or hypothyroid
symptoms, and patients’ preference was equal for both treat-
ments (36). However, it should be noted that serum TSH
levels were higher during T3 substitution, and any possible
improvement might have been obscured by a relative un-
dertreatment of the patients (40).
Sawka et al. (37) evaluated the possible beneficial effects of
T3 substitution in hypothyroid patients presenting with per-
sistent depressive symptoms despite adequate replacement
with levothyroxine alone. Using a randomized parallel de-
sign, 20 patients were assigned to continue with their usual
TABLE 3. Schematic representation of the changes with respect to intact control rats in the plasma concentrations of T4, T3, and TSH
and tissue levels of T4 and T3 of thyroidectomized rats infused with different doses of levothyroxine, alone or in combination with different
doses of liothyronine
0.80 g T4 0.90 g T4
No T3 0.10 g T3 0.15 g T3 0.20 g T3 No T3 0.10 g T3 0.15 g T3 0.20 g T3
T4 T3 TSH T4 T3 TSH T4 T3 TSH T4 T3 TSH T4 T3 TSH T4 T3 TSH T4 T3 TSH T4 T3 TSH
Plasma  2 1   1   1     2 1   1   a   
Cerebral cortex   a      1   a  1   a  
Pituitary  2  2   a   a  2   a    
Cerebellum   a   a   a   a  2   a   a   a
BAT   a 1    a   a  2  1    
Liver  2   a 2    a  2 2 2   a   a
Kidney  2   a   a   a  2  2   a   a
Lung  2  2   a 2   2  2   a   a
Heart  2  2   a 2   2  2   a   a
Spleen  2   a  2   a  2   a     a
Muscle  2   a   a  1  2   a   a   a
Adrenal 1 2 2  2  2    a 1    a  1
Ovary  2   a   a   a  2   a   2 
T4 and T3 doses were administered as micrograms per 100 g per day. The symbols represent the comparison of the mean values of the
thyroidectomized rats infused with different doses of levothyroxine, alone or in combination with different doses of liothyronine, with control
rats infused with placebo., No statistically significant differences;2, low levels as compared with controls, with at least P 0.05;1, elevated
levels as compared with controls, with at least P 0.05. BAT, Brown adipose tissue. [Represented with permission from data published in H. F.
Escobar-Morreale et al.: Endocrinology 137:2490, 1996 (11). The Endocrine Society.]
a In addition to normal T4 and T3 concentrations, the molar T3:T4 ratio was not different from that in the control group.
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levothyroxine dose, and another 20 patients received half
their usual levothyroxine dose plus 12.5 g liothyronine
twice daily (37). The liothyronine dose was titrated thereafter
to maintain serum TSH concentrations within the normal
range. Both treatments were maintained for 15 wk. Patients’
preference was not assessed. No improvement of mood or
hypothyroid symptoms was found with T3 substitution. A
significant proportion of dropouts had occurred in both arms
of treatment and a significant placebo effect detected (symp-
toms were ameliorated with both treatments). More impor-
tantly, power analysis was not provided despite the small
sample size.
Clyde et al. (38) used a randomized parallel design to
evaluate T3 substitution that did not use a crossover design
eliminating the possibility of a practice effect on the tests
used for psychometric performance. In this study, 7.5 g
liothyronine was given twice daily, and 50 g of their levo-
thyroxine dose withdrawn for 16 wk in the patients assigned
to this arm of treatment. Although supported by adequate
statistical power, results from the 44 patients completing the
follow-up did not show any beneficial effect of T3 substitu-
tion on psychometric performance, QoL, mood, and a few
biological end-points of thyroid hormone action. Patients’
preference was not evaluated.
Saravanan et al. (39) used 10 g liothyronine to substitute
50 g of the usual levothyroxine dose of the patients in a
parallel randomized design including 697 patients. The main
outcome was psychiatric caseness, defined by the General
Health Questionnaire 12 score. They found a large and per-
sisting placebo effect in the control group but only a minor
improvement after 3 months of combined treatment, not
sustained thereafter.
Considering the four negative studies published after the
initial report by Bunevicius et al. (30, 32), it would appear that
T3 substitution has a minor role, if any, in thyroid replace-
ment therapy (14, 31, 41). But this did not necessarily exclude
a role of combinations of levothyroxine plus liothyronine in
thyroid replacement therapy, because of important limita-
tions of the T3 substitution approach: 1) considering that the
prestudy levothyroxine requirements were quite variable in
the patients recruited for these studies, this design resulted
in a large variation in the T4:T3 ratios and in the absolute
amounts of both iodothyronines, making it impossible to
mimic normal thyroid physiology (14, 31, 41); 2) these studies
included both men and women, and gender might influence
the response to treatment, especially in terms of mood and
QoL; and 3) the previous duration and severity of hypothy-
roidism were quite variable, including patients presenting at
diagnosis with subclinical hypothyroidism, who might re-
tain some residual secretion of both T4 and T3. Therefore, the
lack of beneficial effects of T3 substitution over levothyroxine
alone might depend on these confounding factors and not on
the lack of an overall beneficial effect of combined levothy-
roxine plus liothyronine replacement therapy.
Four very recent studies (Table 4), including one from our
group, have further contributed to this issue (42–45). Cassio
et al. (42) compared seven infants with congenital hypothy-
roidism treated with levothyroxine alone with seven infants
treated with a levothyroxine plus liothyronine combination
in a molar T4:T3 ratio of 17:1. The levothyroxine dose was
reduced by 20% in the following combination: every 25 g
of the levothyroxine dose calculated for body weight was
substituted by 20 g levothyroxine plus 1 g liothyronine.
Psychomotor development at 6 and 12 months was similarly
impaired with both treatments when compared with euthy-
roid controls. Treatment adjustments based on serum TSH
were more difficult with the combination and more fre-
quently needed.
Siegmund et al. (43) conducted a crossover trial in which
26 hypothyroid patients were treated for 12-wk periods ei-
ther with their usual levothyroxine doses or with a combi-
nation of levothyroxine plus liothyronine. The latter had a
16:1 molar ratio, and under the assumption that bioavail-
ability of oral liothyronine is 100%, and that of levothyroxine
is 90%, the authors hypothesize a 14:1 bioavailable molar
ratio. No improvement of well-being and cognitive perfor-
mance was found with the combination, but the number of
patients completing the study was insufficient to achieve
statistical power (43). No changes were observed in serum
free T4 and free T3, whereas TSH levels were more sup-
pressed with the levothyroxine plus liothyronine combina-
tion, and in eight of the 23 patients analyzed, TSH was
undetectable and associated with an impairment in mood
indexes. Of note, one of the three patients not completing the
study was removed during levothyroxine plus liothyronine
combination treatment because of atrial fibrillation associ-
ated with suppression of TSH. The occurrence of this severe
adverse event raises a cautionary note regarding the addition
to levothyroxine of even very small quantities of liothyronine.
We have published recently a randomized, double-
blinded, crossover clinical trial comparing treatment with
100 g levothyroxine with a combination containing 75 g
levothyroxine plus 5 g liothyronine per day (13:1 molar
T4:T3 ratio, 15:1 by wt). However, fearing possible under-
treatment, all the patients were given, for a final 8-wk add-on
FIG. 2. Plasma PBI values in hypothyroid patients on different com-
binations of levothyroxine plus liothyronine. [Reproduced with per-
mission from S. Taylor et al.: Br Med J 1:270, 1970 (28). © BMJ
Publishing Group.]
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period, a combination containing 87.5 g levothyroxine plus
7.5 g liothyronine per day (10:1 molar T4:T3 ratio, 12:1 by
wt).
We also tried to overcome most of the limitations of pre-
vious studies (Table 4) by using two fixed combinations of
levothyroxine plus liothyronine, in proportions based on
those secreted by the normal thyroid, thus avoiding the vari-
able and excessive amounts of liothyronine compared with
that of levothyroxine used before.
To avoid heterogeneity, we included only female patients
who had long-term overt primary hypothyroidism, making
any interference from residual thyroid function unlikely, and
who had been treated with a 100 g/d dose of levothyroxine
for at least 1 yr before recruitment. Outcomes were not re-
stricted to QoL and psychometric functionality but consisted
in a broad evaluation of thyroid hormone biological end-
points covering most organs and systems. And finally, only
our study included an external control group of healthy
euthyroid women, allowing us to evaluate whether the mea-
sured outcomes were affected in the hypothyroid patients
irrespective of treatment protocol, thus eliminating a poten-
tial confounding factor in previous studies.
Given these strict inclusion criteria, we were able to recruit
only 28 women, of whom 26 completed the study. Yet power
analysis indicated that this sample size was enough to detect
the differences in the QoL, mood, and psychometric indexes
previously reported by Bunevicius et al. (30, 32). Twenty
healthy women served as euthyroid controls.
After treatment with the combination of 75 g levothy-
roxine plus 5 g liothyronine, serum free T4 levels decreased
as compared with levothyroxine alone, whereas TSH in-
creased slightly and free T3 remained unchanged (Fig. 3). On
the contrary, the 87.5 g levothyroxine plus 7.5 g liothy-
ronine combination resulted in over-replacement, given that
TSH levels decreased and free T3 increased compared with
levothyroxine alone (Fig. 3), and in 10 of the patients TSH
levels were below the lower limit of the normal range (but
not suppressed).
We were not able to demonstrate any significant improve-
ment in QoL, mood, or psychometric indexes (44). Patients
scored better in only a few indexes of psychometric perfor-
mance after receiving the combination containing 87.5 g
levothyroxine plus 7.5 g liothyronine, although this slight
improvement might have resulted from overtreatment rather
than from the combined therapy. Of note, our statistical
analysis ruled out any significant period or sequence effect
on the psychometric tests, making significant practice effects
unlikely.
In fact, some items were worse in patients than in euthy-
roid controls, independently of the treatment they received.
As previous studies have shown for hypothyroid patients on
levothyroxine alone (35), it is possible that being aware of
having a disease accounts for this difference (46).
We did not find any improvement in biological end-points
pertaining to multiple organs and systems, including an-
thropometrical, biochemical, hormonal, neurological, and
echocardiographic outcomes. Yet it is important to highlight
that both combinations of levothyroxine plus liothyronine
undesirably increased the urinary concentrations of bone-
remodeling markers.
Patients, however, actually preferred the combinations. Of
the 26 patients, 12 preferred the combination of 75 g levo-
thyroxine plus 5 g liothyronine, six preferred 87.5 g levo-
thyroxine plus 7.5 g liothyronine, two preferred levothy-
roxine alone, and six showed no preference. Although it
might be argued that patients preferred the 87.5 g levo-
thyroxine plus 7.5 g liothyronine combination because of
over-replacement, it should be highlighted that most patients
preferred the 75 g levothyroxine plus 5 g liothyronine
combination, which resulted in the mild under-replacement
suggested by slightly increased TSH and cholesterol values.
This preference for the combined therapy might have re-
sulted from chance. But patients in the Bunevicius et al. (30)
study also preferred levothyroxine plus liothyronine com-
binations, and a similar result has been recently confirmed in
a large study conducted in The Netherlands by Appelhof et
al. (45). One hundred forty-one hypothyroid patients were
randomized to continue on levothyroxine alone, on a com-
bination of levothyroxine plus liothyronine in a molar T4:T3
ratio of 4.2:1 (5:1 by wt), or on combination in a molar T4:T3
ratio of 8.4:1 (10:1 by wt), for 15 wk. The primary outcome
of this trial was patients’ preference, and indexes pertaining
to mood, well-being, and fatigue were considered secondary
outcomes. Study medication was preferred to usual treat-
ment by 29.2% in the levothyroxine group, 41.3% in the 10:1
ratio group, and 52.2% in the 5:1 ratio group. Serum TSH and
body weight decreased with the combinations, especially
with that containing a T4:T3 ratio of 5:1 with which TSH was
actually suppressed in many subjects, as indicated by median
values of 0.07 U/ml. As occurred in our study (44), the
psychological tests used in the Dutch study (45) did not show
any improvement with the levothyroxine plus liothyronine
combinations, and only a minimal reduction in body weight
FIG. 3. Serum TSH, free T4 (FT4), and free T3 (FT3) concentrations
in patients treated with 100 g/d levothyroxine alone (T4100), 75 g
of levothyroxine plus 5 g of liothyronine per day (T475T35), or 87.5
g levothyroxine plus 7.5 g liothyronine per day (T487.5T37.5),
compared with euthyroid controls. Data are means  SD. *, P  0.05
compared with euthyroid controls; †, P  0.05 compared with T4100;
‡, P 0.05 compared with T475T35. [Redrawnwith permission from
H. F. Escobar-Morreale et al.: Ann Intern Med 142:412, 2005 (44). ©
American College of Physicians.]
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was found (mean loss of 0.5 and 1.7 kg in 15 wk with the 10:1
and 5:1 combinations, respectively).
Although most of the limitations of the studies by Smith
et al. (29) and Bunevicius et al. (30) have later been addressed,
the T3 preparation used in all of them was liothyronine,
because at present no sustained-release preparations are
commercially available. For this reason, we were ourselves
(44) unable to follow one of the recommendations emanating
from our animal work (11).
Recently, Hennemann et al. (47) have reported a prelim-
inary description of three 6-wk treatment periods of hypo-
thyroid patients with their usual levothyroxine dose (150
g/d for most of them), followed by 6 wk on a combination
of 125 g levothyroxine plus 6 g liothyronine (in a molar
T4:T3 ratio of 17:1) containing an in-house slow-release T3
preparation and 6 wk on the same combination but using the
Cytomel liothyronine commercial preparation. Lack of in-
formation on the actual chemical nature of the slow-release
preparation precludes confirmation of their findings by
others.
Compared with a similar combination in which T3 was
standard liothyronine, the combination with the slow-release
preparation decreased slightly the maximal serum T3 con-
centration attained and increased slightly the timing of max-
imal concentrations of serum T3 after ingestion, whereas the
area under the curve of serum T3 remained unchanged (47).
Whether these small changes in the pharmacokinetics of
this compound actually represent a major improvement is a
matter of discussion (48), especially when considering that
the mean serum T4, T3, and TSH concentrations of the pa-
tients attained after the standard and after the slow-release
T3 preparations were unchanged and that with the actual
doses of levothyroxine plus liothyronine that were used,
serum T4 concentration remained increased and the serum T3
levels remained low when compared with euthyroid con-
trols, despite the decrease in TSH levels (47).
Summary and Conclusions
In humans, combined levothyroxine plus liothyronine
treatment does not appear to have clear advantages over the
standard treatment with levothyroxine alone. The initial re-
port of beneficial effects of T3 substitution on mood, QoL, and
psychometric functionality has not been confirmed by later
studies, using both T3 substitution and physiological ap-
proaches to combined levothyroxine plus liothyronine re-
placement therapy.
However, in some of these studies, the patients preferred
levothyroxine plus liothyronine combinations over levothy-
roxine alone, for reasons not explained by changes in the
psychological and psychometric tests employed or the bio-
logical end-points that were also measured. Yet patients’
preference should be balanced against the possibility of ad-
verse events resulting from the addition of liothyronine to
levothyroxine, even in the small doses used in these studies.
Therefore, until clear advantages of levothyroxine plus
liothyronine are demonstrated, levothyroxine alone should
remain the drug of choice for the replacement therapy of
hypothyroidism.
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